Karyopharm Therapeutics's total assets for Q4 2025 were $108.42M, an increase of 12.66% from the previous quarter. KPTI total liabilities were $401.34M for the fiscal quarter, a 9.81% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.